Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M90,843Revenue $M7,670Net Margin (%)26.1Z-Score7.2
Enterprise Value $M90,672EPS $2.4Operating Margin %32.8F-Score8
P/E(ttm))47.5Cash Flow Per Share $4.4Pre-tax Margin (%)30.3Higher ROA y-yY
Price/Book13.810-y EBITDA Growth Rate %0Quick Ratio4.4Cash flow > EarningsY
Price/Sales12.45-y EBITDA Growth Rate %23.1Current Ratio4.6Lower Leverage y-yN
Price/Cash Flow17.9y-y EBITDA Growth Rate %39.3ROA % (ttm)13.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)36.7Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M801ROI % (ttm)17.8Gross Margin Increase y-yY

Gurus Latest Trades with CELG

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CELGRonald Muhlenkamp 2014-12-31 Reduce-1.03%$86.38 - $118.68
($105.53)
$ 113.477%Reduce -41.31%86,240
CELGJoel Greenblatt 2014-12-31 Buy 0.01%$86.38 - $118.68
($105.73)
$ 113.477%New holding10,259
CELGGeorge Soros 2014-09-30 Sold Out -0.45%$83.13 - $96.21
($90.29)
$ 113.4720%Sold Out0
CELGJoel Greenblatt 2014-09-30 Sold Out -0.07%$83.13 - $96.21
($90.29)
$ 113.4720%Sold Out0
CELGKen Fisher 2014-09-30 Add0.02%$83.13 - $96.21
($90.29)
$ 113.4720%Add 77.12%232,137
CELGRonald Muhlenkamp 2014-06-30 Reduce-1.91%$68.45 - $86.8
($75.89)
$ 113.4733%Reduce -51.74%144,140
CELGGeorge Soros 2014-06-30 Buy 0.45%$68.45 - $86.8
($75.89)
$ 113.4733%New holding688,000
CELGJoel Greenblatt 2014-06-30 Buy 0.07%$68.45 - $86.8
($75.89)
$ 113.4733%New holding63,980
CELGKen Fisher 2014-06-30 Add0.01%$68.45 - $86.8
($75.89)
$ 113.4733%Add 75.59%131,064
CELGJohn Keeley 2014-03-31 Sold Out $69.65 - $85.97
($79.51)
$ 113.4730%Sold Out0
CELGKen Heebner 2013-06-30 Sold Out -0.79%$56.1 - $65.09
($60.18)
$ 113.4747%Sold Out0
CELGJoel Greenblatt 2013-06-30 Sold Out -0.01%$56.1 - $65.09
($60.18)
$ 113.4747%Sold Out0
CELGGeorge Soros 2011-03-31 Sold Out $24.75 - $30.01
($27.24)
$ 113.4776%Sold Out0
CELGGeorge Soros 2010-03-31 Sold Out -0.01%$27.39 - $32.51
($29.65)
$ 113.4774%Sold Out0
CELGDavid Swensen 2009-12-31 Sold Out $25.11 - $28.66
($27.12)
$ 113.4776%Sold Out0
CELGKen Heebner 2009-09-30 Sold Out -0.28%$23.01 - $28.9
($26.08)
$ 113.4777%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CELG is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CELG: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KAPLAN GILLADirector 2015-02-26Sell15,000$122.89-6.14view
CASEY MICHAEL DDirector 2015-02-25Sell15,000$123.19-6.36view
KARSEN PERRY Asee remarks 2015-02-11Sell27,896$120.12-3.97view
Alles Mark JSee Remarks 2015-02-06Sell117,099$120.68-4.42view
STEIN LAWRENCE VSee Remarks 2015-01-15Sell26,666$120.01-3.88view
KAPLAN GILLADirector 2015-01-02Sell45,536$113.471.66view
Daniel Thomas Osee remarks 2014-12-15Sell30,000$115.060.25view
KAPLAN GILLADirector 2014-12-08Sell15,000$118.2-2.41view
Daniel Thomas Osee remarks 2014-11-24Sell33,818$110.274.61view
KARSEN PERRY Asee remarks 2014-11-12Sell39,420$107.237.57view

Press Releases about CELG :

Quarterly/Annual Reports about CELG:

News about CELG:

Articles On GuruFocus.com
February Pick Of Biotech Stocks Feb 17 2015 
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Nov 18 2014 
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Coun Nov 17 2014 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
Weekly 52-Week Highs Highlight: ALL, SRE, CLX, CELG Oct 06 2014 
Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
You Can No Longer Ignore Biotech Feb 07 2014 

More From Our Partners
Stock Market News for April 09, 2015 - Market News Apr 9 2015 - ZACKS

More From Other Websites
Midday Glance: Biotechnology companies Apr 14 2015
Midday Glance: Biotechnology companies Apr 14 2015
Five companies that may be looking to buy Ariad Pharmaceuticals Apr 14 2015
Early Glance: Biotechnology companies Apr 14 2015
Early Glance: Biotechnology companies Apr 14 2015
So You Want to Be a Short Seller… Apr 14 2015
Can a Small New Stem Cell Pact Move the Needle for Celgene? Apr 13 2015
Bullish earnings play in Celgene Apr 13 2015
Market's Moment of Truth: Brace for Earnings Apr 13 2015
Short Sellers Increase Their Bets Against Biotech Stocks Apr 13 2015
7:29 am Celgene: Mesoblast (MBLTY) announces that it has... Apr 13 2015
China equities at 7-year highs; Tokyo struggles to cross 20000 mark Apr 13 2015
Mesoblast Jumps Most in 4 Years as Celgene Invests $45 Million Apr 12 2015
Celgene And Mesoblast Enter Into Agreement Apr 12 2015
Biotech Stock Mailbag: Biogen's Alzheimer's Update, Celgene Patent Worries, Receptos, MannKind Apr 10 2015
Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blog Apr 08 2015
Top trades for the 2nd half Apr 08 2015
Mylan makes bid for Perrigo Apr 08 2015
OncoMed Collaborates with Eli Lilly for Oncology Candidate - Analyst Blog Apr 06 2015
Morphosys CEO says MOR202 drug candidate still promising - newspaper Apr 04 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK